US FDA says Ranbaxy has to forfeit exclusivity for capsules to treat stomach and aesophagus problems

Published: 30-Jan-2015
Regulatory Pharmaceutical

US regulator revokes tentative approvals for two Ranbaxy generics


The US FDA has determined that the Indian drug manufacturer Ranbaxy forfeit its 180 days exclusivity for esomeprazole magnesium delayed release capsules used to treat stomach and aesophagus problems.

Ranbaxy says it is 'disappointed' with the result and is 'pursuing all available legal options to preserve its rights'.

In November 2014, the US regulator revoked its tentative approvals for Ranbaxy's generic anti viral drug valganciclovir hydrochloride and esomeprazole magnesium delayed release capsules 20mg and 40mg.

While the FDA said Ranbaxy's abbreviated new drug application (ANDA) did not have any data integrity issues, it added that its 'original decisions granting tentative approvals were in error, because of the compliance status of the facilities referenced in the ANDAs at the time the tentative approvals were granted'.

  • Companies:
  • Sun Pharmaceutical Industries
See more

You may also like

Finance

Sun Pharma to operate manufacturing plants in Japan

Read more
India's drugmaker taps into dermatology market with acquisition of Japan-based Pola Pharma

Trending Articles

  1. Navigating regulatory challenges in pharmaceutical packaging: lessons from the past and strategies for the future To safeguard drug efficacy, maintain strict quality standards and ensure patient safety, pharmaceutical packaging is subject to a wide range of regulations around the world, reports Kun Shing Chan, Director of QA at Tjoapack
  2. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  3. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  4. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Finance

Sun Pharma to operate manufacturing plants in Japan

India's drugmaker taps into dermatology market with acquisition of Japan-based Pola Pharma
Pharmaceutical

Sun Pharma opens new cGMP production line in India

The Mumbai-based company has installed a production line in Guwahati to enhance the manufacturing capacity of sterile products
Regulatory

Several large Indian pharma companies under US FDA scrutiny

Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Pharmaceutical

Sun Pharma launches generic version of Novartis' anti-leukaemia drug Gleevec in US

In 2015 the product had total sales of US$4.5bn globally and $2.5bn in the US, according to IMS data
Regulatory

Sun Pharma Global recalls osteoporosis drug in US

After an 'unknown purity' was discovered in cartons of alendronate sodium tablets
Pharmaceutical

Indian generic manufacturers aim to enter the Japanese market

The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Finance

Sun Pharmaceutical plans to purchase a portion of Novartis branded products in Japan

Will gain a foothold in Japan with speciality dermatology drugs anda portfolio of generics
Subscribe now